Oral mucositis incidence and severity after methotrexate- and non-methotrexate-containing GVHD prophylaxis regimens  by Cutler, C. et al.
Oral Presentations
ALLOGENEIC
7
ORAL MUCOSITIS INCIDENCE AND SEVERITY AFTER METHOTREXATE-
AND NON-METHOTREXATE-CONTAINING GVHD PROPHYLAXIS REGI-
MENS
Cutler, C.; Li, S.; Kim, H.T.; Laglenne, P.; Ford, C.; Ho, V.; Lee, S.;
Alyea, E.; Soiffer, R.; Sonis, S.; Antin, J. Dana Farber Cancer Institute
and Brigham and Women’s Hospital, Harvard Medical School, Boston,
MA.
Oral mucositis (OM) occurs in up to 75% of recipients of high-
dose chemoradiotherapy conditioning regimens prior to allogeneic
HSCT. As a result of OM, narcotic analgesia and total parenteral
nutrition (TPN) are commonly required after HSCT. Methotrex-
ate (MTX), an antiproliferative GVHD prophylaxis agent, impairs
mucosal regeneration and worsens and prolongs OM. We assessed
the impact of the substitution of sirolimus for MTX as GVHD
prophylaxis on outcomes associated with OM. Methods: 2 patient
cohorts were prospectively analyzed for OM severity and retro-
spectively reviewed for correlative outcomes. All patients under-
went Cy-TBI conditioning and HLA-matched sibling PBSC trans-
plantation. GVHD prophylaxis consisted of sirolimus/tacrolimus
(ST) in the study group and tacrolimus/methotrexate (TM) in the
control group. OM was assessed 3 times per week by members of
the Oral Medicine Service, using a prospectively validated 6-point
assessment tool. Narcotic and TPN use was recorded from the
time of transplantation to hospital discharge. Results: 30 patients
received ST and 24 patients received TM as GVHD prophylaxis
between October 2000 and May 2003. The 2 groups were balanced
for demographic variables, including age, sex, and disease status at
transplant. OM severity was reduced in the ST group. Mild, mod-
erate, and severe OM was noted in 37%, 57%, and 7% of the ST
group and in 8%, 42%, and 50% of the TM group, respectively
(P  .0002). TPN use was reduced in the ST group (17% vs 43%
of hospital days; P  .02), and a higher proportion of subjects
required no TPN in the ST group (47% vs 21%; P  .075). The
total number of narcotic days was lower in the ST group in
comparison with the TM group (median, 13.5 vs. 17 days; P .08),
as was the total mg of morphine-equivalents (MME) administered
per patient (median, 880 vs 1225 mg, P not signiﬁcant [NS]), the
median number of MME per hospital day (41.2 vs 61.7 mg; P 
NS) and the median MME per narcotic day (61.9 vs 95.2 mg; P 
NS). The time to ﬁrst hospital discharge was shorter in the ST
group compared with the TM group (median, 18 vs 22 days; P 
.07). Conclusions: The substitution of sirolimus for methotrexate
as GVHD prophylaxis is associated with a reduction in OM sever-
ity. As a result, TPN and narcotic use are reduced, and hospital-
ization duration is shortened. The use of less toxic GVHD regi-
mens without MTX may have signiﬁcant impact on patient quality
of life, patient outcomes,and economic outcomes associated with
allogeneic stem cell transplantation.
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THE ROLE OF REDUCED-INTENSITY CONDITIONING (RIC) ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLO-SCT) IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA (AML): A DONOR VERSUS NO DONOR COMPAR-
ISON
De Lavallade, H.; Mohty, M.; Faucher, C.; Vey, N.; Coso, D.; Stoppa,
A.M.; Gastaut, J.A.; Ladaique, P.; Chabannon, C.; Blaise, D. Institut
Paoli-Calmettes, Marseille, France.
The role and exact beneﬁt of RIC allo-SCT for AML patients is
still under considerable investigation. Our current policy is to
propose an HLA-identical RIC allo-SCT to AML patients with
high risk leukemic features and with age ( 50 years) and/or
comorbidities precluding the use of standard myeloablative allo-
SCT. We report here a single-center retrospective study that
aimed to evaluate this treatment strategy, and to determine
whether or not all AML patients with high-risk leukemic features
and high-risk clinical features with a suitable HLA-identical sibling
should receive RIC allo-SCT. Between 1999 and 2003, 95 AML
(77% de novo and 23% secondary) patients in complete remission
(93 in ﬁrst CR, 2 in second or third CR) and alive 40 days after
diagnosis were considered as potential candidates for RIC allo-
SCT. Median age was 52 years (range, 26–65). Of the 95 patients,
35 (37%, “donor” group) had an HLA-identical related donor, and
allo-SCT was carried out in 25 (71%) after a RIC based on
ﬂudarabine (150 mg/kg), ATG (2.5 mg/kg), and Bus (8mg/kg). A
total of 60 patients had no donor (63%, “no donor” group). There
were no signiﬁcant differences between the 2 groups with respect
to age, gender, FAB subtype, disease origin (secondary vs de novo)
cytogenetic risk group, history of prior high-dose cytarabine or
autologous transplantation and number of chemotherapy induction
courses. With a median follow-up of 432 days (range, 27–1651), in
an intend-to-treat analysis, LFS was signiﬁcantly higher in the
“donor” group than in the “no donor” group (P  .0096; 54% vs
30.4%, respectively). A total of 32 patients (53%) relapsed in the
no donor group during the follow-up period, as compared to 9
(26%) in the donor group (P .0087). Among the 35 patients with
an HLA-identical related donor, 10 did not receive allo-SCT for
the following reasons: early relapse (2 patients), refusal (4), toxicity
of previous chemotherapy (2), and psychiatric disorder appeared on
therapy (2). For the transplanted patients, little procedure-related
toxicities were observed, and the cumulative incidence of trans-
plant-related mortality was low (12%; 95%CI, 3%-32%) for this
group of elderly high-risk AML patients. We conclude that a
potent graft-versus-leukemia effect can be induced in AML pa-
tients after RIC allo-SCT, with a signiﬁcant beneﬁt in term of
leukemia-free survival.
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SIROLIMUS AND TACROLIMUS AS GRAFT-VERSUS-HOST DISEASE PRO-
PHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION: THE DANA
FARBER CANCER INSTITUTE EXPERIENCE
Cutler, C.; Li, S.; Kim, H.T.; Alyea, E.; Ho, V.; Lee, S.J.; Soiffer, R.;
Antin, J. Dana-Farber Cancer Institute and Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA.
Sirolimus is a novel immunosuppressant that inhibits T-cell
function through FKBP12/mTOR and can impair dendritic cell
function. Sirolimus acts synergistically with tacrolimus and has a
nonoverlapping toxicity proﬁle, making their use in combination
attractive. We began using sirolimus as GVHD prophylaxis in
2000, and herein describe our experience in the myeloablative
setting. Methods: Two clinical trials were performed using Cy/
TBI conditioning with sirolimus (3–12 ng/ml) and tacrolimus
(5–10 ng/ml) as GVHD prophylaxis. Trial 1 enrolled 76 subjects
who received HLA-matched unrelated or 1-Ag mismatched related
or unrelated bone marrow or peripheral blood stem cells. Abbre-
viated methotrexate (20 mg/m2 total) was given posttransplant.
Trial 2 enrolled 53 subjects who received HLA-matched related
peripheral blood stem cells. No methotrexate was given posttrans-
plant. Results: The median times to neutrophil engraftment (
500/l) were 17 days (range, 11–32) for trial 1 and 14 days (range,
9–17) for trial 2. The median times to platelet engraftment (
20,000/l) were 29 days (range, 11–98) for trial 1 and 12 days
(range, 10–47) for trial 2. Grade II-IV acute GVHD occurred in
35% of the patients in trial 1 and in 19% of the patients in trial 2.
Grade III-IV acute GVHD occurred in 21% of patients in trial 1
and in 4% of patients in trial 2. Toxicity related to the addition of
sirolimus was modest. Among all patients (n  129), VOD oc-
curred in 12%, idiopathic pneumonia syndrome occurred in 7%,
and thrombotic microangiopathy occurred in 10%. The median
time to ﬁrst hospital discharge was 33 days from transplantation for
trial 1 and 19 days from transplantation for trial 2. The percentage
of patients who did not survive to ﬁrst hospital discharge was 9%
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